Rami Elghandour
Chairman & Chief Executive Officer
San Francisco Bay Area · 1 connectionNot on Unlinked · Imported profile. Is this you? Claim it
Is this about you? Request removal
About
Rami Elghandour is Chairman and CEO of Arcellx (NASDAQ: ACLX), a biotechnology company developing transformative immunotherapies for cancer and autoimmune diseases. Rami has led two successful IPOs, built two multibillion-dollar public companies, and raised more than $1.75 billion in capital. Since joining in 2021, Rami transformed Arcellx from a small, early-stage startup into a leading, commercial-ready organization. During his tenure, he advanced anito-cel, the best therapeutic option for multiple myeloma, and drove a more than fortyfold increase in value with its acquisition by Gilead for $8.2 billion in April 2026. Previously, Rami was President and CEO of Nevro Corporation (formerly NYSE: NVRO), a global medical device company. Rami scaled the company from 30 employees to nearly 1,000, increasing its value by more than tenfold and reaching a peak valuation of over $3 billion. Rami’s career has spanned research, investing, and leadership roles with a dedication to bringing innovative, best-in-class therapies to patients and clinicians. He started his career as a design engineer designing and developing implantable neurostimulators. As a venture capitalist with Johnson and John
Experience
Jun 2026
Nov 2025
Nov 2025 to Apr 2026
Sep 2001 to Jun 2006
Education
MBA, Health Care Management, Management
2006 to 2008